Advertisement
U.S. markets closed
Advertisement

VolitionRx Limited (VNRX)

NYSE American - NYSE American Delayed Price. Currency in USD
Visitors trend2W10W9M
0.6367-0.0203 (-3.09%)
At close: 03:58PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Performance Outlook
Previous Close0.6570
Open0.6715
Bid0.6102 x 1300
Ask0.7000 x 900
Day's Range0.6255 - 0.6999
52 Week Range0.5800 - 2.7400
Volume137,039
Avg. Volume186,818
Market Cap50.099M
Beta (5Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)-0.5200
Earnings DateNov 15, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.76
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VNRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • VolitionRX Limited
    Analyst Report: Guardant Health, Inc.Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
    Rating
    Fair Value
    Economic Moat
    12 days agoMorningstar
View more